boehringer glp 1 Boehringer's GLP-1 dual agonist survodutide shines in phase III trial | News What Patients Need to Know

Tirzepatide is a new drug that helps lose weight

Abstract Osteoarthritis (OA) is the most common chronic joint disease worldwide

What really gets me is the no shortcuts marketing, which shames people for choosing proven treatments

This positioning highlights their growing relevance as a bridge between conservative and invasive treatments, offering a balance between efficacy, safety, and feasibility in pediatric obesity management

While there is a potential for metabolic synergy, the risks of low blood sugar and severe digestive upset are real

Cerebrolysin has the strongest evidence base for neurological recovery scenarios